We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Orion Corp (ORNBV) Ser B NPV

Sell:€42.58 Buy:€42.60 Change: €0.53 (1.25%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:€42.58
Buy:€42.60
Change: €0.53 (1.25%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:€42.58
Buy:€42.60
Change: €0.53 (1.25%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Orion Oyj, previously Orion Corporation, is a Finland-based company active within the pharmaceutical industry. The Company is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.

Contact details

Address:
Orionintie 1A
ESPOO
02200
Finland
Telephone:
+358 (10) 4261
Website:
https://www.orion.fi/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ORNBV
ISIN:
FI0009014377
Market cap:
€5.95 billion
Shares in issue:
140.50 million
Sector:
Pharmaceuticals
Exchange:
Helsinki Stock Exchange
Country:
Finland
Currency:
Euro
Indices:
OMX Helsinki 25

Key personnel

  • Liisa Hurme
    President, Chief Executive Officer, Member of the Executive Management Board
  • Rene Lindell
    Chief Financial Officer, Member of the Executive Management Board
  • Julia Macharey
    Senior Vice President - People and Culture, Member of the Executive Management Board
  • Satu Ahomaki
    Senior Vice President, Generics and Consumer Health, Member of the Executive Management Board
  • Juhani Kankaanpaa
    Senior Vice President, Global Operations, Fermion, Member of the Executive Management Board
  • Niclas Lindstedt
    Senior Vice President, Animal Health, Member of the Executive Management Board
  • Hao Pan
    Senior Vice President, Branded Products, Member of the Executive Management Board
  • Outi Vaarala
    Senior Vice President for Research and Development and Innovative Medicines, Member of the Executive Management Board
  • Olli Huotari
    Senior Vice President, Corporate Functions; Member of the Executive Management Board; Secretary
  • Jani Korhonen
    Employee Representative on the Executive Management Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.